The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Venetoclax for AML
Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, outlines the use of venetoclax, a BCL-2 inhibitor, in acute myeloid leukemia (AML) and caveats associated with its use, including moving this treatment beyond its approved indication in unfit, relapsed/refractory AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
